{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:49:12Z","timestamp":1740163752267,"version":"3.37.3"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T00:00:00Z","timestamp":1602201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T00:00:00Z","timestamp":1602201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001742","name":"United States-Israel Binational Science Foundation","doi-asserted-by":"crossref","award":["2015361","2015361"],"award-info":[{"award-number":["2015361","2015361"]}],"id":[{"id":"10.13039\/501100001742","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Accumulating evidence indicates that persistent <jats:italic>Helicobacter pylori<\/jats:italic> gastric infection influences immune responses to oral enteric vaccines. We studied the association between pre-existing <jats:italic>H. pylori<\/jats:italic> serum IgG and serum pepsinogens levels (PGs) as markers of gastric inflammation and the immune response to single-dose live oral cholera vaccine CVD 103-HgR in Malian adults. Baseline sera obtained during a phase 2 safety\/immunogenicity clinical trial of cholera vaccine CVD 103-HgR among 93 healthy Malian adults were tested for <jats:italic>H. pylori<\/jats:italic> IgG antibodies and PGI and PGII levels using enzyme linked immunosorbent assays. Overall 74\/93 (80%) vaccine recipients were <jats:italic>H. pylori<\/jats:italic> IgG seropositive at baseline. Vibriocidal antibody seroconversion (\u2265\u2009fourfold increase 14\u00a0days following administration of CVD 103-HgR compared to baseline) among vaccine recipients was 56%. However, vibriocidal antibody seroconversion was markedly higher among <jats:italic>H. pylori<\/jats:italic> seropositives than seronegatives 64% vs. 26% (<jats:italic>p<\/jats:italic>\u2009=\u20090.004); adjusted relative risk: 2.20 (95% confidence intervals 1.00\u20134.80; <jats:italic>p<\/jats:italic>\u2009=\u20090.049). Among <jats:italic>H. pylori<\/jats:italic> seropositive vaccine recipients, there were no significant associations between PGI, PGII and PGI:PGII levels and vibriocidal seroconversion. The enhanced seroconversion to oral cholera vaccine CVD 103-HgR among <jats:italic>H. pylori<\/jats:italic> seropositive African adults provides further evidence of the immunomodulating impact of <jats:italic>H. pylori<\/jats:italic> on oral vaccine immunogenicity.<\/jats:p>","DOI":"10.1038\/s41598-020-71754-9","type":"journal-article","created":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T10:02:37Z","timestamp":1602237757000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pre-existing Helicobacter pylori serum IgG enhances the vibriocidal antibody response to CVD 103-HgR live oral cholera vaccine in Malian adults"],"prefix":"10.1038","volume":"10","author":[{"given":"Khitam","family":"Muhsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samba O.","family":"Sow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milagritos D.","family":"Tapia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fadima C.","family":"Haidara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mardi","family":"Reymann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Asato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilbur H.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcela F.","family":"Pasetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myron M.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,9]]},"reference":[{"key":"71754_CR1","doi-asserted-by":"publisher","first-page":"791","DOI":"10.2217\/fmb.15.19","volume":"10","author":"AS Bandyopadhyay","year":"2015","unstructured":"Bandyopadhyay, A. S., Garon, J., Seib, K. & Orenstein, W. A. Polio vaccination: past, present and future. Future Microbiol. 10, 791\u2013808. https:\/\/doi.org\/10.2217\/fmb.15.19 (2015).","journal-title":"Future Microbiol."},{"key":"71754_CR2","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1093\/infdis\/jix186","volume":"215","author":"E Burnett","year":"2017","unstructured":"Burnett, E., Jonesteller, C. L., Tate, J. E., Yen, C. & Parashar, U. D. Global impact of rotavirus vaccination on childhood hospitalizations and mortality from diarrhea. J. Infect. Dis. 215, 1666\u20131672. https:\/\/doi.org\/10.1093\/infdis\/jix186 (2017).","journal-title":"J. Infect. Dis."},{"issue":"Suppl 1","key":"71754_CR3","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1086\/518141","volume":"45","author":"MM Levine","year":"2007","unstructured":"Levine, M. M. et al. Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B. Clin. Infect. Dis. 45(Suppl 1), S24-28. https:\/\/doi.org\/10.1086\/518141 (2007).","journal-title":"Clin. Infect. Dis."},{"key":"71754_CR4","doi-asserted-by":"publisher","first-page":"e0006759","DOI":"10.1371\/journal.pntd.0006759","volume":"12","author":"JS Gauld","year":"2018","unstructured":"Gauld, J. S., Hu, H., Klein, D. J. & Levine, M. M. Typhoid fever in Santiago, Chile: Insights from a mathematical model utilizing venerable archived data from a successful disease control program. PLoS Negl. Trop. Dis. 12, e0006759. https:\/\/doi.org\/10.1371\/journal.pntd.0006759 (2018).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"71754_CR5","doi-asserted-by":"publisher","first-page":"e952","DOI":"10.1371\/journal.pntd.0000952","volume":"5","author":"R Reyburn","year":"2011","unstructured":"Reyburn, R. et al. The case for reactive mass oral cholera vaccinations. PLoS Negl. Trop. Dis. 5, e952. https:\/\/doi.org\/10.1371\/journal.pntd.0000952 (2011).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"71754_CR6","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/1741-7007-8-129","volume":"8","author":"MM Levine","year":"2010","unstructured":"Levine, M. M. Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine. BMC Biol. 8, 129. https:\/\/doi.org\/10.1186\/1741-7007-8-129 (2010).","journal-title":"BMC Biol."},{"key":"71754_CR7","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1553593","author":"AD Steele","year":"2019","unstructured":"Steele, A. D. et al. Experiences with rotavirus vaccines: can we improve rotavirus vaccine impact in developing countries?. Hum. Vaccin. Immunother. https:\/\/doi.org\/10.1080\/21645515.2018.1553593 (2019).","journal-title":"Hum. Vaccin. Immunother."},{"key":"71754_CR8","doi-asserted-by":"publisher","first-page":"6341","DOI":"10.1128\/IAI.67.12.6341-6345.1999","volume":"67","author":"CO Tacket","year":"1999","unstructured":"Tacket, C. O. et al. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination. Infect. Immun. 67, 6341\u20136345 (1999).","journal-title":"Infect. Immun."},{"key":"71754_CR9","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/14760584.2017.1291348","volume":"16","author":"MM Levine","year":"2017","unstructured":"Levine, M. M. et al. PaxVax CVD 103-HgR single-dose live oral cholera vaccine. Expert Rev. Vaccines. 16, 197\u2013213. https:\/\/doi.org\/10.1080\/14760584.2017.1291348 (2017).","journal-title":"Expert Rev. Vaccines."},{"key":"71754_CR10","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1093\/cid\/ciw145","volume":"62","author":"WH Chen","year":"2016","unstructured":"Chen, W. H. et al. ingle-dose live oral cholera vaccine CVD 103-HgR protects against human experimental infection with Vibrio cholerae O1 El Tor. Clin. Infect. Dis. 62, 1329\u20131335. https:\/\/doi.org\/10.1093\/cid\/ciw145 (2016).","journal-title":"Clin. Infect. Dis."},{"key":"71754_CR11","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1093\/infdis\/165.6.1042","volume":"165","author":"P Su-Arehawaratana","year":"1992","unstructured":"Su-Arehawaratana, P. et al. Safety and immunogenicity of different immunization regimens of CVD 103-HgR live oral cholera vaccine in soldiers and civilians in Thailand. J. Infect. Dis. 165, 1042\u20131048 (1992).","journal-title":"J. Infect. Dis."},{"key":"71754_CR12","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/0140-6736(92)92231-4","volume":"340","author":"Suharyono","year":"1992","unstructured":"Suharyono, et al. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children. Lancet 340, 689\u2013694 (1992).","journal-title":"Lancet"},{"key":"71754_CR13","doi-asserted-by":"publisher","first-page":"3994","DOI":"10.1128\/IAI.61.9.3994-3997.1993","volume":"61","author":"E Gotuzzo","year":"1993","unstructured":"Gotuzzo, E. et al. Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels. Infect. Immun. 61, 3994\u20133997 (1993).","journal-title":"Infect. Immun."},{"key":"71754_CR14","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1086\/315051","volume":"180","author":"R Lagos","year":"1999","unstructured":"Lagos, R. et al. Effect of small bowel bacterial overgrowth on the immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR. J. Infect. Dis. 180, 1709\u20131712. https:\/\/doi.org\/10.1086\/315051 (1999).","journal-title":"J. Infect. Dis."},{"key":"71754_CR15","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1128\/IAI.63.2.707-709.1995","volume":"63","author":"R Lagos","year":"1995","unstructured":"Lagos, R. et al. Attenuated live cholera vaccine strain CVD 103-HgR elicits significantly higher serum vibriocidal antibody titers in persons of blood group O. Infect. Immun. 63, 707\u2013709 (1995).","journal-title":"Infect. Immun."},{"key":"71754_CR16","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1086\/315837","volume":"182","author":"PJ Cooper","year":"2000","unstructured":"Cooper, P. J. et al. Albendazole treatment of children with ascariasis enhances the vibriocidal antibody response to the live attenuated oral cholera vaccine CVD 103-HgR. J. Infect. Dis. 182, 1199\u20131206. https:\/\/doi.org\/10.1086\/315837 (2000).","journal-title":"J. Infect. Dis."},{"key":"71754_CR17","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1093\/aje\/155.11.1054","volume":"155","author":"AMY Nomura","year":"2002","unstructured":"Nomura, A. M. Y., Perez-Perez, G. I., Lee, J., Stemmermann, G. & Blaser, M. J. Relation between Helicobacter pylori cagA status and risk of peptic ulcer disease. Am J. Epidemiol. 155, 1054\u20131059 (2002).","journal-title":"Am J. Epidemiol."},{"key":"71754_CR18","first-page":"2111","volume":"55","author":"MJ Blaser","year":"1995","unstructured":"Blaser, M. J. et al. Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res. 55, 2111\u20132115 (1995).","journal-title":"Cancer Res."},{"key":"71754_CR19","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1056\/NEJMra020542347\/15\/1175[pii]","volume":"347","author":"S Suerbaum","year":"2002","unstructured":"Suerbaum, S. & Michetti, P. Helicobacter pylori infection. N. Engl. J. Med. 347, 1175\u20131186. https:\/\/doi.org\/10.1056\/NEJMra020542347\/15\/1175[pii] (2002).","journal-title":"N. Engl. J. Med."},{"key":"71754_CR20","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1172\/JCI38605","volume":"119","author":"JC Atherton","year":"2009","unstructured":"Atherton, J. C. & Blaser, M. J. Coadaptation of Helicobacter pylori and humans: ancient history, modern implications. J. Clin. Invest. 119, 2475\u20132487 (2009).","journal-title":"J. Clin. Invest."},{"key":"71754_CR21","doi-asserted-by":"crossref","unstructured":"Muhsen, K. et al. Age-dependent association among Helicobacter pylori infection, serum pepsinogen levels and immune response of children to live oral cholera vaccine CVD 103-HgR. PLoS ONE ARTN e8399910.1371\/journal.pone.0083999 (2014).","DOI":"10.1371\/journal.pone.0083999"},{"key":"71754_CR22","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1093\/infdis\/jit625","volume":"209","author":"K Muhsen","year":"2014","unstructured":"Muhsen, K., Pasetti, M. F., Reymann, M. K., Graham, D. Y. & Levine, M. M. Helicobacter pylori infection affects immune responses following vaccination of typhoid-naive US adults with attenuated Salmonella Typhi oral vaccine CVD 908-htrA. J. Infect. Dis. 209, 1452\u20131458. https:\/\/doi.org\/10.1093\/infdis\/jit625 (2014).","journal-title":"J. Infect. Dis."},{"key":"71754_CR23","doi-asserted-by":"crossref","unstructured":"Sow, S. O. et al. Randomized, placebo-controlled, double-blind phase 2 trial comparing the reactogenicity and immunogenicity of a single standard dose to those of a high dose of CVD 103-HgR live attenuated oral cholera vaccine, with Shanchol inactivated oral vaccine as an open-label immunologic comparator. Clin. Vaccine Immunol. 24, doi:UNSP e00265\u20131710.1128\/CVI.00265\u201317 (2017).","DOI":"10.1128\/CVI.00265-17"},{"key":"71754_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1471-230X-14-3","volume":"14","author":"XM Zhang","year":"2014","unstructured":"Zhang, X. M., Li, J. X., Zhang, G. Y., Li, X. H. & Gu, H. The value of serum pepsinogen levels for the diagnosis of gastric diseases in Chinese Han people in midsouth China. BMC Gastroenterol. 14, 3. https:\/\/doi.org\/10.1186\/1471-230X-14-3 (2014).","journal-title":"BMC Gastroenterol."},{"key":"71754_CR25","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1111\/j.1365-2036.2005.02734.x","volume":"22","author":"G Nardone","year":"2005","unstructured":"Nardone, G. et al. Diagnostic accuracy of the serum profile of gastric mucosa in relation to histological and morphometric diagnosis of atrophy. Aliment. Pharmacol. Ther. 22, 1139\u20131146. https:\/\/doi.org\/10.1111\/j.1365-2036.2005.02734.x (2005).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"71754_CR26","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0016-5085(19)33596-6","volume":"61","author":"IM Samloff","year":"1971","unstructured":"Samloff, I. M. Cellular localization of group I pepsinogens in human gastric mucosa by immunofluorescence. Gastroenterology 61, 185\u2013188 (1971).","journal-title":"Gastroenterology"},{"key":"71754_CR27","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/S0016-5085(19)33138-5","volume":"65","author":"IM Samloff","year":"1973","unstructured":"Samloff, I. M. & Liebman, W. M. Cellular localization of the group II pepsinogens in human stomach and duodenum by immunofluorescence. Gastroenterology 65, 36\u201342 (1973).","journal-title":"Gastroenterology"},{"key":"71754_CR28","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1443-9573.2007.00278.x","volume":"8","author":"K Miki","year":"2007","unstructured":"Miki, K. & Urita, Y. Using serum pepsinogens wisely in a clinical practice. J. Dig. Dis. 8, 8\u201314. https:\/\/doi.org\/10.1111\/j.1443-9573.2007.00278.x (2007).","journal-title":"J. Dig. Dis."},{"key":"71754_CR29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3109\/00365529109103997","volume":"439\u2013440","author":"M Kekki","year":"1991","unstructured":"Kekki, M., Samloff, I. M., Varis, K. & Ihamaki, T. Serum pepsinogen I and serum gastrin in the 438 screening of severe atrophic corpus gastritis. Scand. J. Gastroenterol. 439\u2013440, 109\u2013116 (1991).","journal-title":"Scand. J. Gastroenterol."},{"key":"71754_CR30","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1443-9573.2007.00271.x","volume":"8","author":"Q Cao","year":"2007","unstructured":"Cao, Q., Ran, Z. H. & Xiao, S. D. Screening of atrophic gastritis and gastric cancer by. J. Dig. Dis. 8, 15\u201322. https:\/\/doi.org\/10.1111\/j.1443-9573.2007.00271.x (2007).","journal-title":"J. Dig. Dis."},{"key":"71754_CR31","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.cgh.2005.11.003","volume":"4","author":"DY Graham","year":"2006","unstructured":"Graham, D. Y. et al. Noninvasive versus histologic detection of gastric atrophy in a Hispanic population in North America. Clin. Gastroenterol. Hepatol. 4, 306\u2013314. https:\/\/doi.org\/10.1016\/j.cgh.2005.11.003 (2006).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"71754_CR32","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/sj.bjc.6600877","volume":"88","author":"N Broutet","year":"2003","unstructured":"Broutet, N. et al. Pepsinogen A, pepsinogen C, and gastrin as markers of atrophic chronic gastritis in European dyspeptics. Br. J. Cancer. 88, 1239\u20131247. https:\/\/doi.org\/10.1038\/sj.bjc.6600877 (2003).","journal-title":"Br. J. Cancer."},{"key":"71754_CR33","doi-asserted-by":"publisher","first-page":"e024689","DOI":"10.1136\/bmjopen-2018-024689","volume":"9","author":"K Muhsen","year":"2019","unstructured":"Muhsen, K. et al. Prevalence and determinants of serological evidence of atrophic gastritis among Arab and Jewish residents of Jerusalem: a cross-sectional study. BMJ Open. 9, e024689. https:\/\/doi.org\/10.1136\/bmjopen-2018-024689 (2019).","journal-title":"BMJ Open."},{"key":"71754_CR34","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0140-6736(13)60844-2","volume":"382","author":"KL Kotloff","year":"2013","unstructured":"Kotloff, K. L. et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet 382, 209\u2013222. https:\/\/doi.org\/10.1016\/S0140-6736(13)60844-2 (2013).","journal-title":"Lancet"},{"key":"71754_CR35","doi-asserted-by":"publisher","first-page":"e568","DOI":"10.1016\/S2214-109X(19)30076-2","volume":"7","author":"KL Kotloff","year":"2019","unstructured":"Kotloff, K. L. et al. The incidence, aetiology, and adverse clinical consequences of less severe diarrhoeal episodes among infants and children residing in low-income and middle-income countries: a 12-month case-control study as a follow-on to the Global Enteric Multicenter Study (GEMS). Lancet Glob. Health. 7, e568\u2013e584. https:\/\/doi.org\/10.1016\/S2214-109X(19)30076-2 (2019).","journal-title":"Lancet Glob. Health."},{"key":"71754_CR36","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1093\/cid\/ciu468","volume":"59","author":"S Livio","year":"2014","unstructured":"Livio, S. et al. Shigella isolates from the global enteric multicenter study inform vaccine development. Clin. Infect. Dis. 59, 933\u2013941. https:\/\/doi.org\/10.1093\/cid\/ciu468 (2014).","journal-title":"Clin. Infect. Dis."},{"key":"71754_CR37","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1128\/JCM.27.1.162-167.1989","volume":"27","author":"D Cohen","year":"1989","unstructured":"Cohen, D., Block, C., Green, M. S., Lowell, G. & Ofek, I. Immunoglobulin M, A, and G antibody response to lipopolysaccharide O antigen in symptomatic and asymptomatic Shigella infections. J. Clin. Microbiol. 27, 162\u2013167 (1989).","journal-title":"J. Clin. Microbiol."},{"key":"71754_CR38","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1093\/aje\/kwg074","volume":"157","author":"LA McNutt","year":"2003","unstructured":"McNutt, L. A., Wu, C., Xue, X. & Hafner, J. P. Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am. J. Epidemiol. 157, 940\u2013943. https:\/\/doi.org\/10.1093\/aje\/kwg074 (2003).","journal-title":"Am. J. Epidemiol."},{"key":"71754_CR39","volume-title":"N","author":"P McCullagh","year":"1983","unstructured":"McCullagh, P. N (Chapman and Hall, J. Generalized linear models. Second edition. edn, 1983)."},{"key":"71754_CR40","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1093\/aje\/kwi188","volume":"162","author":"D Spiegelman","year":"2005","unstructured":"Spiegelman, D. & Hertzmark, E. Easy SAS calculations for risk or prevalence ratios and differences. Am. J. Epidemiol. 162, 199\u2013200. https:\/\/doi.org\/10.1093\/aje\/kwi188 (2005).","journal-title":"Am. J. Epidemiol."},{"key":"71754_CR41","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1080\/00365521.2017.1315739","volume":"52","author":"XT Wang","year":"2017","unstructured":"Wang, X. T. et al. The correlation between histological gastritis staging\u2014\"OLGA\/OLGIM\u2019 and serum pepsinogen test in assessment of gastric atrophy\/intestinal metaplasia in China. Scand. J. Gastroenterol. 52, 822\u2013827. https:\/\/doi.org\/10.1080\/00365521.2017.1315739 (2017).","journal-title":"Scand. J. Gastroenterol."},{"key":"71754_CR42","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/hel.12112","volume":"19","author":"JH Nam","year":"2014","unstructured":"Nam, J. H. et al. OLGA and OLGIM stage distribution according to age and Helicobacter pylori status in the Korean population. Helicobacter. 19, 81\u201389. https:\/\/doi.org\/10.1111\/hel.12112 (2014).","journal-title":"Helicobacter."},{"key":"71754_CR43","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/S0140-6736(95)91084-0","volume":"345","author":"EJ Kuipers","year":"1995","unstructured":"Kuipers, E. J. et al. Long-term sequelae of Helicobacter pylori gastritis. Lancet 345, 1525\u20131528. https:\/\/doi.org\/10.1016\/S0140-6736(95)91084-0 (1995).","journal-title":"Lancet"},{"key":"71754_CR44","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1542\/peds.104.2.216","volume":"104","author":"PS Ganga-Zandzou","year":"1999","unstructured":"Ganga-Zandzou, P. S. et al. Natural outcome of Helicobacter pylori infection in asymptomatic children: a two-year follow-up study. Pediatrics 104, 216\u2013221 (1999).","journal-title":"Pediatrics"},{"key":"71754_CR45","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/tropej\/fmr068","volume":"58","author":"K Muhsen","year":"2012","unstructured":"Muhsen, K., Jurban, M., Goren, S. & Cohen, D. Incidence, age of acquisition and risk factors of Helicobacter pylori infection among Israeli Arab infants. J. Trop. Pediatr. 58, 208\u2013213. https:\/\/doi.org\/10.1093\/tropej\/fmr068 (2012).","journal-title":"J. Trop. Pediatr."},{"key":"71754_CR46","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1053\/j.gastro.2009.01.073","volume":"136","author":"TL Cover","year":"2009","unstructured":"Cover, T. L. & Blaser, M. J. Helicobacter pylori in health and disease. Gastroenterology 136, 1863\u20131873 (2009).","journal-title":"Gastroenterology"},{"key":"71754_CR47","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.3748\/wjg.v25.i25.3183","volume":"25","author":"S Smith","year":"2019","unstructured":"Smith, S., Fowora, M. & Pellicano, R. Infections with Helicobacter pylori and challenges encountered in Africa. World J. Gastroenterol. 25, 3183\u20133195. https:\/\/doi.org\/10.3748\/wjg.v25.i25.3183 (2019).","journal-title":"World J. Gastroenterol."},{"key":"71754_CR48","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1136\/gut.33.4.429","volume":"33","author":"C Holcombe","year":"1992","unstructured":"Holcombe, C. Helicobacter pylori: the African enigma. Gut 33, 429\u2013431. https:\/\/doi.org\/10.1136\/gut.33.4.429 (1992).","journal-title":"Gut"},{"key":"71754_CR49","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/s0140-6736(78)91568-4","volume":"2","author":"DR Nalin","year":"1978","unstructured":"Nalin, D. R. et al. Cholera, non-vibrio cholera, and stomach acid. Lancet 2, 856\u2013859. https:\/\/doi.org\/10.1016\/s0140-6736(78)91568-4 (1978).","journal-title":"Lancet"},{"key":"71754_CR50","doi-asserted-by":"publisher","first-page":"271","DOI":"10.7326\/0003-4819-78-2-271","volume":"78","author":"RA Giannella","year":"1973","unstructured":"Giannella, R. A., Broitman, S. A. & Zamcheck, N. Influence of gastric acidity on bacterial and parasitic enteric infections. A perspective.  Ann. Intern. Med. 78, 271\u2013276 (1973).","journal-title":"Ann. Intern. Med."},{"key":"71754_CR51","first-page":"31","volume":"47","author":"GH Sack Jr","year":"1972","unstructured":"Sack, G. H. Jr. et al. Gastric acidity in cholera and noncholera diarrhoea. Bull. World Health Organ. 47, 31\u201336 (1972).","journal-title":"Bull. World Health Organ."},{"key":"71754_CR52","first-page":"349","volume":"51","author":"O Schiraldi","year":"1974","unstructured":"Schiraldi, O., Benvestito, V., Di Bari, C., Moschetta, R. & Pastore, G. Gastric abnormalities in cholera: epidemiological and clinical considerations. Bull. World Health Organ. 51, 349\u2013352 (1974).","journal-title":"Bull. World Health Organ."},{"key":"71754_CR53","first-page":"663","volume":"7","author":"S Gitelson","year":"1971","unstructured":"Gitelson, S. Gastrectomy, achlorhydria and cholera. Isr. J. Med. Sci. 7, 663\u2013667 (1971).","journal-title":"Isr. J. Med. Sci."},{"key":"71754_CR54","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1093\/infdis\/171.6.1653","volume":"171","author":"J Clemens","year":"1995","unstructured":"Clemens, J. et al. Impact of infection by Helicobacter pylori on the risk and severity of endemic cholera. J. Infect. Dis. 171, 1653\u20131656 (1995).","journal-title":"J. Infect. Dis."},{"key":"71754_CR55","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.trstmh.2005.09.013","volume":"100","author":"R Leon-Barua","year":"2006","unstructured":"Leon-Barua, R. et al. Helicobacter pylori-associated chronic atrophic gastritis involving the gastric body and severe disease by Vibrio cholerae. Trans. R. Soc. Trop. Med. Hyg. 100, 567\u2013572. https:\/\/doi.org\/10.1016\/j.trstmh.2005.09.013 (2006).","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"71754_CR56","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S0140-6736(99)05143-0","volume":"355","author":"ML Shahinian","year":"2000","unstructured":"Shahinian, M. L. et al. Helicobacter pylori and epidemic Vibrio cholerae O1 infection in Peru. Lancet 355, 377\u2013378 (2000).","journal-title":"Lancet"},{"key":"71754_CR57","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1086\/345762","volume":"186","author":"MK Bhan","year":"2002","unstructured":"Bhan, M. K. et al. Association between Helicobacter pylori infection and increased risk of typhoid fever. J. Infect. Dis. 186, 1857\u20131860 (2002).","journal-title":"J. Infect. Dis."},{"key":"71754_CR58","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1017\/S0950268805004875","volume":"134","author":"AM Vollaard","year":"2006","unstructured":"Vollaard, A. M. et al. Helicobacter pylori infection and typhoid fever in Jakarta, Indonesia. Epidemiol. Infect. 134, 163\u2013170. https:\/\/doi.org\/10.1017\/S0950268805004875 (2006).","journal-title":"Epidemiol. Infect."},{"key":"71754_CR59","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1172\/JCI22","volume":"102","author":"A Mattsson","year":"1998","unstructured":"Mattsson, A., Lonroth, H., Quiding-Jarbrink, M. & Svennerholm, A. M. Induction of B cell responses in the stomach of Helicobacter pylori- infected subjects after oral cholera vaccination. J. Clin. Invest. 102, 51\u201356. https:\/\/doi.org\/10.1172\/JCI22 (1998).","journal-title":"J. Clin. Invest."},{"key":"71754_CR60","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1111\/cea.12995","volume":"47","author":"B Taye","year":"2017","unstructured":"Taye, B. et al. Association between infection with Helicobacter pylori and atopy in young Ethiopian children: A longitudinal study. Clin. Exp. Allergy. 47, 1299\u20131308. https:\/\/doi.org\/10.1111\/cea.12995 (2017).","journal-title":"Clin. Exp. Allergy."},{"key":"71754_CR61","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1093\/cid\/cir916","volume":"54","author":"D Cohen","year":"2012","unstructured":"Cohen, D., Shoham, O., Orr, N. & Muhsen, K. An inverse and independent association between Helicobacter pylori infection and the incidence of shigellosis and other diarrheal diseases. Clin. Infec. Dis. 54, e35-42. https:\/\/doi.org\/10.1093\/cid\/cir916 (2012).","journal-title":"Clin. Infec. Dis."},{"key":"71754_CR62","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1086\/315887","volume":"182","author":"D Rothenbacher","year":"2000","unstructured":"Rothenbacher, D., Blaser, M. J., Bode, G. & Brenner, H. Inverse relationship between gastric colonization of Helicobacter pylori and diarrheal illnesses in children: results of a population-based cross-sectional study. J. Infect. Dis. 182, 1446\u20131449. https:\/\/doi.org\/10.1086\/315887 (2000).","journal-title":"J. Infect. Dis."},{"key":"71754_CR63","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1080\/19490976.2017.1376162","volume":"9","author":"V Harris","year":"2018","unstructured":"Harris, V. et al. Rotavirus vaccine response correlates with the infant gut microbiota composition in Pakistan. Gut Microbes. 9, 93\u2013101. https:\/\/doi.org\/10.1080\/19490976.2017.1376162 (2018).","journal-title":"Gut Microbes."},{"key":"71754_CR64","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/infdis\/jiw518","volume":"215","author":"VC Harris","year":"2017","unstructured":"Harris, V. C. et al. Significant correlation between the infant gut microbiome and rotavirus vaccine response in rural Ghana. J. Infect. Dis. 215, 34\u201341. https:\/\/doi.org\/10.1093\/infdis\/jiw518 (2017).","journal-title":"J. Infect. Dis."},{"key":"71754_CR65","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.chom.2018.07.005","volume":"24","author":"VC Harris","year":"2018","unstructured":"Harris, V. C. et al. Effect of antibiotic-mediated microbiome modulation on rotavirus vaccine immunogenicity: a human, randomized-control proof-of-Concept trial. Cell Host Microbe. 24, 197. https:\/\/doi.org\/10.1016\/j.chom.2018.07.005 (2018).","journal-title":"Cell Host Microbe."},{"key":"71754_CR66","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1053\/j.gastro.2017.04.022","volume":"153","author":"JKY Hooi","year":"2017","unstructured":"Hooi, J. K. Y. et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology 153, 420\u2013429. https:\/\/doi.org\/10.1053\/j.gastro.2017.04.022 (2017).","journal-title":"Gastroenterology"},{"key":"71754_CR67","doi-asserted-by":"publisher","DOI":"10.1088\/1752-7155\/10\/3\/036012","author":"M Maiga","year":"2016","unstructured":"Maiga, M. et al. Stool microbiome reveals diverse bacterial ureases as confounders of oral urea breath testing for Helicobacter pylori and Mycobacterium tuberculosis in Bamako. Mali. J. Breath Res. https:\/\/doi.org\/10.1088\/1752-7155\/10\/3\/036012 (2016).","journal-title":"Mali. J. Breath Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-71754-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-71754-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-71754-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T20:54:36Z","timestamp":1670360076000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-71754-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,9]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["71754"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-71754-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2020,10,9]]},"assertion":[{"value":"6 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Professor Levine is the co-inventor of CVD 103-HgR which is commercialized by Emergent Biosolutions, Gaithersburg, MD as Vaxchora. The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16871"}}